Publication date: Dec 12, 2019
This activity is designed to meet the educational needs of physicians, nurses and nurse midwives, advanced practice clinicians, and pharmacists, who manage patients with multiple sclerosis (MS).
Multiple sclerosis (MS) has a female predominance of approximately 3 to 1 and appears to be increasing among young women who are of reproductive age at the time of diagnosis. The impact of the disease and its treatment on the health of a pregnant mother and the developing fetus is a critical issue. While it may seem prudent to recommend that women discontinue disease-modifying therapy (DMT) before pregnancy or if a pregnancy is confirmed, this decision must be made on a case-by-case basis. Healthcare professionals require the latest information about DMT use during pregnancy, including available data on approved therapies and labeling recommendations that may influence this decision-making process.
Commercial Support Acknowledgement
This webinar is supported by an educational grant from Bayer HealthCare Pharmaceuticals
Valid for Credit Through: December 31, 2020
For more information please visit https://cmscscholar.org/reproductive-health-planning
- How Can We Apply Guidelines in the Rapidly Changing MS Treatment Landscape?
- Advancing Multiple Sclerosis Treatment and Outcomes: Access, Adherence and Site of Care Obstacles
- Vitamin D and MS